Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
RESEARCH TOOLSreports
Holding CYTH?
Track your performance easily
CYTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $2.12
Previous Close$0.65
Volume19.08K
Average Volume (3M)76.01K
Market Cap
$19.37M
Enterprise Value$20.56M
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 12, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding28,696,028
10 Day Avg. Volume51,813
30 Day Avg. Volume76,012
Standard Deviation0.22
R-Squared0.00729
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.62
Price to Sales (P/S)16.47
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.15
Enterprise Value/Gross Profit20.72
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$0.95Price Target Upside40.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cyclo Therapeutics News
PremiumCompany Announcements
Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings
Bulls Say, Bears Say
Bulls Say
Clinical MilestoneThe completion of enrollment in the largest controlled pivotal study for NPC1 ever conducted is a major milestone, with top-line data expected from the 48-week interim analysis in the first quarter of 2025.
Drug DevelopmentThe company announced it has completed enrollment for its 108-patient pivotal phase 3 trial of its lead drug candidate.
Patent ApprovalThe company received notice from the European Patent Office of a decision to grant a European patent application.
Bears Say
EarningsThe company reported a net loss of $0.21 per diluted share, which was worse than the consensus estimate of a net loss of $0.16 per diluted share.
Operating ExpensesOperating expenses for the quarter were significantly higher than estimated, coming in at $5.8 million versus an estimate of $5.1 million.
Stock RatingThe stock rating was downgraded from Buy to Neutral, and the price target was significantly reduced from $3.00 per share to $0.95 per share.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTH FAQ
What was Cyclo Therapeutics’s price range in the past 12 months?
Cyclo Therapeutics lowest stock price was $0.59 and its highest was $2.12 in the past 12 months.
What is Cyclo Therapeutics’s market cap?
Currently, no data Available
When is Cyclo Therapeutics’s upcoming earnings report date?
Cyclo Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Cyclo Therapeutics’s earnings last quarter?
Cyclo Therapeutics released its earnings results on Aug 15, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.055.
Is Cyclo Therapeutics overvalued?
According to Wall Street analysts Cyclo Therapeutics’s price is currently Undervalued.
Does Cyclo Therapeutics pay dividends?
Cyclo Therapeutics does not currently pay dividends.
What is Cyclo Therapeutics’s EPS estimate?
Cyclo Therapeutics’s EPS estimate is -$0.16.
How many shares outstanding does Cyclo Therapeutics have?
Cyclo Therapeutics has 28,696,028 shares outstanding.
What happened to Cyclo Therapeutics’s price movement after its last earnings report?
Cyclo Therapeutics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went up 1.681%.
Which hedge fund is a major shareholder of Cyclo Therapeutics?
Currently, no hedge funds are holding shares in CYTH
---
Cyclo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.95 (40.76% Upside)
$0.95 (40.76% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Cyclo Therapeutics
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
---
CYTH Stock 12 Month Forecast
Average Price Target
$0.95
▲(40.76% Upside)
Technical Analysis
Best Analysts Covering CYTH
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-34.75%
assigned a buy rating 25 days ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.75% per trade.
---